Latest News:
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries
New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019
Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA
US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV
ar
de
el
en
fr
it
TIF
About
Education
Country work
Positions & Policies
Projects
Publications
News & Events
Contact
Home
»
Upcoming Events
Find Events
Event Views Navigation
View As
List
Month
Events From
Search
There were no results found.
«
Previous Events
Cookies
This site uses cookies.
Find out more
Okay, thanks